Consun Pharmaceutical Group Limited (SEHK:1681) commences share repurchases on January 3, 2019, under the program mandated by the shareholders in the Annual General Meeting held on May 30, 2018. As per the mandate, the company is authorized to repurchase up to 87,468,588 shares, representing 10% of its issued share capital. The repurchases will result in an increase in the net asset value and/or earnings per share. The repurchase program will be funded out of funds legally available for the purpose in accordance with the Memorandum and Articles of Association, the Listing Rules, and any other applicable laws of the Cayman Islands. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual general Meeting is required to be held or the date on which the authority is varied, revoked or renewed in a General Meeting. As at May 30, 2018, the company had 874,685,880 shares in issue.